Brief: Sino Biopharmaceutical Says LM-350 CDH17 Antibody-Drug Conjugate Receives Clinical Trial Approval From China's NMPA
18/11/2025 10:19
Nov 18 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: LM-350 CDH17 ANTIBODY-DRUG CONJUGATE RECEIVES CLINICAL TRIAL APPROVAL FROM CHINA'S NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit